Research progress of targeted protein degradation

Yixuan Chen

doi:10.1117/12.2669970

24 March 2023 Research progress of targeted protein degradation

Yixuan Chen

Proceedings Volume 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022); 126112F (2023) https://doi.org/10.1117/12.2669970
Event: International Conference on Biological Engineering and Medical Science (ICBioMed2022), 2022, Oxford, United Kingdom

Abstract

Most diseases are related to the abnormal expression or activity of proteins. Currently, most of the drugs are protein inhibitors. However, the number of pathogenic proteins suitable for binding inhibitors is limited, and most of the potential pathogenic proteins cannot become drug targets. Targeted protein degradation technology is a new technology that can specifically recognize the marked protein and straightly degrade the protein through a degradation pathway inside the cell. The paper, through a method of literature review, explores TPD technologies through proteasome and lysosome pathways. The paper concludes that technologies related to the proteasome are represented by PROTAC. In addition to PROTAC, tri-PROTAC, molecular glues, dTAGs, SNIPERS, and trim-way are also emerging technologies based on the UPS systems. Moreover, targeted protein stabilization (TPS) is also a hot topic, focusing on the stabilization instead of degradation in TPD, so the concept of DUBTACs has been put forward. Those associated with the lysosome include LYTAC and its derivatives. LYTAC is a new technique that provokes extracellular and membrane protein degradation through the endosome-lysosome pathway. Besides, TPD solves the problem caused by the lack of inhibitors. Consequently, it has broken through many bottlenecks of drug research in existence, providing new ways and possibilities for the development of medication.

Citation Download Citation

Yixuan Chen "Research progress of targeted protein degradation", Proc. SPIE 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022), 126112F (24 March 2023); https://doi.org/10.1117/12.2669970

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available